Commit Biologics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$60M
- Investors
-
9
Commit Biologics General Information
Description
Developer of complement-powered immune engagers intended for oncology and autoimmune diseases. The company utilizes a proprietary bispecific complement engager platform and antibody engineering to provide complement-powered immune engagers, bispecific antibodies, oncology immunotherapies, autoimmune disease therapies, B cell depletion candidates, and modular antibody constructs, enabling healthcare providers to eliminate diseased cells through targeted activation of the innate immune system.
Contact Information
Website
www.commitbio.comCorporate Office
- Nordre Fasanvej 215
- 2000 Frederiksberg
- Denmark
Corporate Office
- Nordre Fasanvej 215
- 2000 Frederiksberg
- Denmark
Commit Biologics Timeline
Commit Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Seed Round | 17-Nov-2026 | $60M | Completed | Pre-Clinical Trials | ||
| 5. Seed Round | 28-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 09-May-2024 | Completed | Startup | |||
| 3. Grant | 14-Feb-2024 | Completed | Startup | |||
| 2. Accelerator/Incubator | 14-Sep-2021 | $589K | $589K | Completed | Startup | |
| 1. University Spin-Out | 16-Aug-2021 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Commit Biologics Patents
Commit Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202417958-D0 | Engineered complement engaging polypeptides | Inactive | 06-Dec-2024 | ||
| GB-202417959-D0 | Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof | Inactive | 06-Dec-2024 | ||
| WO-2025229159-A1 | Antibodies and antibody constructs against cd20 | Pending | 01-May-2024 | ||
| WO-2025229158-A1 | Antibodies and antibody constructs against cd38 | Pending | 01-May-2024 | ||
| WO-2025229161-A1 | Engineered complement engaging polypeptides | Pending | 01-May-2024 | A61P35/00 |
Commit Biologics Signals
Commit Biologics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Ackermans & van Haaren | Growth/Expansion | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| Bioqube Ventures | Venture Capital | Minority | ||
| Korys Investments | Family Office | Minority |
Commit Biologics FAQs
-
When was Commit Biologics founded?
Commit Biologics was founded in 2021.
-
Where is Commit Biologics headquartered?
Commit Biologics is headquartered in Frederiksberg, Denmark.
-
What is the size of Commit Biologics?
Commit Biologics has 35 total employees.
-
What industry is Commit Biologics in?
Commit Biologics’s primary industry is Drug Discovery.
-
Is Commit Biologics a private or public company?
Commit Biologics is a Private company.
-
What is Commit Biologics’s current revenue?
The current revenue for Commit Biologics is .
-
How much funding has Commit Biologics raised over time?
Commit Biologics has raised $100M.
-
Who are Commit Biologics’s investors?
AbbVie Ventures, Ackermans & van Haaren, M Ventures, Bioqube Ventures, and Korys Investments are 5 of 9 investors who have invested in Commit Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process